Halozyme Therapeutics (HALO) EBT Margin (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly EBT Margin of 47.87% for Q1 2026, down 643.0% year-over-year from 8.82% in Q1 2025, and up 314.44% quarter-over-quarter from 22.32% in Q4 2025.
Halozyme Therapeutics (HALO) EBT Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported EBT Margin for 17 consecutive years, with 47.87% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 643.0% year-over-year to 47.87%; the TTM figure through Mar 2026 stood at 33.37% (down 2242.0% YoY), while the FY2025 annual figure was 33.43%, down 2144.0% from the prior year.
- EBT Margin advanced to 47.87% in Q1 2026 per HALO's latest filing, from 22.32% in the prior quarter.
- Across five years, EBT Margin topped out at 63.45% in Q1 2022 and bottomed at 22.32% in Q4 2025.
- Historically, EBT Margin has averaged 43.77% across 5 years, with a median of 47.87% in 2026.
- Annual changes were most pronounced in 2022 — EBT Margin soared 3190 bps — and 2025, when it slumped 8212 bps.
- Halozyme Therapeutics' EBT Margin stood at 39.0% in 2022, then climbed by 13 bps to 43.98% in 2023, then jumped by 36 bps to 59.8% in 2024, then sank by 137 bps to 22.32% in 2025, then surged by 314 bps to 47.87% in 2026.
- Business Quant data shows HALO's EBT Margin at 47.87% in Q1 2026, 22.32% in Q4 2025, and 61.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 59.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.23% |
| Mar 31, 2026 | 47.87% |
| Dec 31, 2025 | -22.32% |
| Sep 30, 2025 | 61.81% |
| Jun 30, 2025 | 62.92% |
| Mar 31, 2025 | 54.30% |
| Dec 31, 2024 | 59.80% |
| Sep 30, 2024 | 56.93% |
| Jun 30, 2024 | 50.89% |
| Mar 31, 2024 | 49.02% |
| Dec 31, 2023 | 43.98% |
| Sep 30, 2023 | 47.10% |
| Jun 30, 2023 | 42.14% |
| Mar 31, 2023 | 32.22% |
| Dec 31, 2022 | 39.00% |
| Sep 30, 2022 | 35.27% |
| Jun 30, 2022 | 19.70% |
| Mar 31, 2022 | 63.45% |
| Dec 31, 2021 | 53.73% |
| Sep 30, 2021 | 63.98% |